Latest from Atlantic Health System

Eric Whitman, MD, medical director of Atlantic Health System Cancer Care, Atlantic Health System, discusses ways to expand the benefit of immunotherapy in non-immunogenic solid tumors.
Eytan M. Stein, MD, internist, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses recent advances that have been made in the treatment of patients with acute myeloid leukemia (AML).
Missak Haigentz, MD, chief of Hematology and Oncology at Morristown Medical Center and medical director of Atlantic Hematology and Oncology for Atlantic Medical Group at the Carol G. Simon Cancer Center, discusses the potential of erlotinib (Tarceva) and bevacizumab (Avastin) in EGFR-mutant non–small cell lung cancer (NSCLC).
Balazs Halmos, MD, discusses the latest developments in the treatment paradigm for patients with squamous cell non–small cell lung cancer.
Missak Haigentz, MD, discusses the impact of EGFR TKIs on the treatment of patients with non–small cell lung cancer.
Neil Morganstein, MD, discusses the intriguing PACIFIC results and the future role of immunotherapy in non–small cell lung cancer. 
Mark Widmann, MD, discusses the role of surgery in the treatment of patients with early-stage lung cancer.
Hossein Borghaei, DO, MS, discusses immunotherapy selection for the treatment of patients with non–small cell lung cancer.
Publication Bottom Border
Border Publication